MyChesCo on MSN6d
ChromaTan and Landmark Bio Receive NIIMBL Grant to Advance AAV Gene Therapy Manufacturing
ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing ...
GEN - Genetic Engineering and Biotechnology News6d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Labmate Online13d
Expanded kit range enhances AAV vector characterisation
Bio-Rad Laboratories, Inc has introduced Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 ...
The American Journal of Managed Care7d
Data Gaps Leave Long-Term Impact of Ex Vivo Gene Therapy in DMD Uncertain
Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.
Yahoo Finance12d
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
The initiation of this study with the dual AAV vector gene therapy, SB-007, represents a critical advancement in finding a potential treatment option for patients with this disease. It is a ...
Labmate Online12d
Expanded manufacturing enhances life science capabilities
ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...
Medindia12d
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
The initiation of this study with the dual AAV vector gene therapy, SB-007, represents a critical advancement in finding a potential treatment option for patients with this disease. It is a privilege ...